Category Archives: Eczema

Canada is poised to become the first country in the world to require that a warning be printed on every cigarette. The move builds on Canadas mandate to include graphic photo warnings on tobacco products packaging a policy that started an international trend when it was introduced two decades ago.

We need to address the concern that these messages may have lost their novelty, and to an extent we worry that they may have lost their impact as well, minister of mental health and addictions Carolyn Bennett said at a news conference on Friday. Adding health warnings on individual tobacco products will help ensure that these essential messages reach people, including the youth who often access cigarettes one at a time in social situations, sidestepping the information printed on a package.

A consultation period for the proposed change is set to begin on Saturday, and the government anticipates the changes coming into force in the latter half of 2023. While the exact messaging printed on cigarettes could change, Ms Bennett said the current proposal is: Poison in every puff.

She also revealed expanded warnings for cigarette packages that include a longer list of smokings health effects, including stomach cancer, colorectal cancer, diabetes, and peripheral vascular disease. Canada has required the photo warnings since the turn of the millennium, but the images have not been updated in a decade.

Rob Cunningham, senior policy analyst with the Canadian Cancer Society, said he hopes the warnings printed directly on cigarettes become popular internationally, just like the package warnings did.

This is going to set a world precedent, Mr Cunningham said, adding no other country has implemented such regulations. He is hopeful that the warning will make a real difference. Its a warning that you simply cannot ignore. Its going to reach every smoker, with every puff.

Smoking rates have been steadily falling over the years. The latest data from Statistics Canada (StatCan), released last month, shows 10% of Canadians reported smoking regularly. The government is seeking to cut that rate in half by 2035. StatCan noted that roughly 11% of Canadians 20 and older reported being current smokers, compared to just 4% of people aged 15 to 19.

For stories from where you live, visit InYourArea.

Read this article:
Canada to require a warning be printed on every cigarette - Coventry Live

Essential oils are commonly used in the treatment of acne, rosacea, eczema, and other skin conditions. A good example is rosemary essential oil, which may help destroy Propionibacterium acnes, the bacterium responsible for acne breakouts, reports a 2007 study published in Planta Medica. You may also try tea tree oil for its antibacterial and anti-inflammatory effects. This natural remedy is rich in terpenes, limonene, and other phytochemicals that may help kill common bacterial strains like P. acnes, S. aureus, Lactobacillus, and E. coli, according to 2015 research featured in the journal Clinical Microbiology Reviews.

Another option is lavender essential oil, which can accelerate healing and prevent acne scars. David Karlak and Susan Griffin-Black, two experts interviewed by Byrdie, also recommend cypress, rosehip seed, or jojoba oil. For example, rose oil contains farnesol, a compound that soothes dry skin and reduces excess sebum, notes Griffin-Black.

Remember to dilute your favorite essential oils with a carrier oil before applying them to the skin. These products are very concentrated and may cause irritation if used undiluted. As a general rule, add one drop of essential oil for every three drops of coconut, avocado, or olive oil, suggests doTerra. Lavender essential oil can be used as is, but it's best to dilute it if you have sensitive skin.

Go here to read the rest:
Holistic Acne Treatments That Are Better Than What You've Been Doing - The List

BARCELONA, Spain, June 7, 2022 /PRNewswire/ -- Almirall S.A. (BME: ALM) today announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, an investigational IL-13 inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 clinical trials (ADvocate 1 and 2) showed eight out of ten patients who achieved clinical response (EASI-75*) with lebrikizumab monotherapy at 16 weeks maintained skin clearance at one year of treatment with the once every two weeks or four weeks regimen. Additionally, patients treated with lebrikizumab maintained itch relief across the two trials over the one-year period. These results build upon positive datafrom the 16-week, double-blind, placebo-controlled part of the ADvocate program.

"We are pleased to witness how lebrikizumab has proven over a year its potential to be a leading option for the treatment of atopic dermatitis. ADvocate 1 and 2 results add to the exciting, growing body of evidence from our Phase 3 clinical trial program and demonstrate that this medicine may provide much-needed relief for those seeking new treatment options. We look forward to continuing our collaboration with Lilly and advancing in our clinical program, aiming to obtain approval in the European Union," stated Karl Ziegelbauer, Ph.D., Almirall's Chief Scientific Officer.

AD, or atopic eczema, is a chronic, relapsing, heterogenous skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.1-2 Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin-13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R1/IL-4R(Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.3-7 IL-13 plays the central role in AD, promoting Type 2 inflammation that drives skin barrier dysfunction, itch, skin thickening and infection.8-10

In ADvocate 1, 79% of patients who received lebrikizumab every four weeks and 79% of patients who received lebrikizumab every two weeks maintained 75% or greater skin improvement (EASI-75) at one year of treatment. Additionally, 85% of patients who received lebrikizumab every four weeks and 77% of patients who received lebrikizumab every two weeks maintained EASI-75 response in ADvocate 2 at one year of treatment.

The frequency of adverse events and the overall safety profile among these patients treated with lebrikizumab were consistent with the induction phase of the trials as well as previous lebrikizumab studies in AD. No new safety signals were observed in this patient population.

"In these studies, patients treated with lebrikizumab maintained skin clearance and lasting relief from intense itch at one year. We look forward to providing an important new medicine and helping patients find the relief they so desperately seek from the varied and debilitating symptoms of this disease, contingent upon FDA approval," said Lotus Mallbris, M.D., Ph.D., vice president of global immunology development and medical affairs at Eli Lilly and Company.

With these data, Almirall plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for lebrikizumab in AD in the second half of 2022. Lilly also plans to submit an application to the U.S. Food and Drug Administration (FDA) this year, followed by submissions to other regulatory agencies around the world.

These studies are part of the comprehensive clinical development program for lebrikizumab in AD evaluating more than 2,000 patients. Full one-year results from the Phase 3 monotherapy studies will be disclosed at upcoming congresses and in publications in 2022. Additional Phase 3 clinical trials are enrolling for lebrikizumab in AD.

Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. Lilly has exclusive rights for development and commercialization of lebrikizumab in the United States and the rest of the world outside Europe.

*EASI=Eczema Area and Severity Index, EASI-75=75 percent reduction in EASI from baseline to Week 16

About ADvocate 1 and ADvocate 2 and the Phase 3 Program

ADvocate 1andADvocate 2are 52-week randomized, double-blind, placebo-controlled, parallel-group, global, Phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients (aged 12 to less than 18 years of age and weighing at least 40 kg) with moderate-to-severe AD.During the 16-week treatment period, patients received lebrikizumab 500-mg initially and at two weeks, followed by lebrikizumab 250-mg or placebo every two weeks. In the maintenance period, patients with moderate-to-severe AD who achieved a clinical response after 16 weeks of lebrikizumab treatment were re-randomized to receive lebrikizumab every two weeks or every four weeks or placebo for an additional 36 weeks.Patients who required rescue treatment during the induction period or who did not achieve clinical response (lebrikizumab non-responders) at 16 weeks received lebrikizumab every two weeks for an additional 36 weeks.The primary endpoints were measured by an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with a reduction of at least two points from baseline and at least 75 percent change in baseline in the Eczema Area and Severity Index (EASI-75) score at 16 weeks. EASI measures extent and severity of the disease. Key secondary endpoints were measured by IGA, EASI, the Pruritus Numeric Rating Scale, Sleep-Loss due to Pruritus and the Dermatology Life Quality Index.

The U.S. Food and Drug Administration (FDA) granted lebrikizumab Fast Track designation in AD in December 2019. The lebrikizumab Phase 3 program consists of five key global studies including two monotherapy studies, a combination study (ADhere), as well as long-term extension (ADjoin) and adolescent open label (ADore) studies.

About Lebrikizumab

Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity to specifically prevent the formation of the IL-13R1/IL-4R heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is the central pathogenic mediator of AD, promoting Type 2 inflammation that drives skin barrier dysfunction, itch, skin thickening and infection.6-8

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.

For more information, please visit almirall.com

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

1Weidinger S, Novak N. Lancet. 2016;387:1109-1122.2Langan SM, et al. Arch Dermatol. 2008;142:1109.3Moyle M, et al. Exp Dermatol. 2019;28(7):756-768.4 Ultsch M, et al. J Mol Biol. 2013;425(8):1330-1339.5Zhu R, et al. Pulm Pharmacol Ther. 2017;46:88-98.6Simpson EL, et al. J Am Acad Dermatol. 2018;78(5):863-871.e11.7Okragly A, et al. Comparison of the Affinity and in vitro Activity of Lebrikizumab, Tralokinumab, and Cendakimab. Presented at the Inflammatory Skin Disease Summit, New York, November 3-6, 2021.8Tsoi L, et al. Journal of Investigative Dermatology. 2019;139(7):1480-1489.9Ratnarajah K, et al. Journal of Cutaneous Medicine and Surgery. 2021;25(3):315-328.10Bieber T. Allergy. 2020;75(1):54-62.

Logo - https://mma.prnewswire.com/media/1217694/Almirall_Logo.jpg

SOURCE Almirall, S.A.

Originally posted here:
Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials - PR Newswire UK

A call centre operator plagued by such virulent eczema she was left balding, bedbound and slept in a balaclava to stop her oozing face from sticking to the pillow says a life-changing 9 cream cleared her skin overnight.

While Kimberley Reardon, 30, suffered with mild baby eczema until she was three-years-old, it did not flare-up again until her teens and it was only in her 20s that her catastrophic problems began and she was covered from head-to-toe in red raw patches of the dry, flaking skin condition.

For the next decade, her eczema frequently developed into painful, weeping sores and saw Kimberley trying numerous steroid creams.

However, the treatements would work only briefly, before the angry conditionreturned with such vigour she would be unable to move without her skin weeping or peeling.

After several hospitalisations, infections and periods of being bedbound, by March 2022 Kimberley, who lives with her boyfriend of 12 years, healthcare assistant, Scott Hannah, 31, had lost hope only for her mum to stumble upon 8.99 Balmonds Skin Salvation cream that practically cleared her skin overnight.

Kimberley, of Hamilton, South Lanarkshire, Scotland, said: I was exhausted and hopeless. It felt like it was never ending.

I had spent nearly 10 years in chronic pain and itwas an achievement for me to just get myself washed and dressed in the morning.

I have tried so many creams that dont work, so when my mum suggested I tried this one, I was very sceptical about it working.

But, when I woke up the next day, my face was almost clear it was unbelievable.

Kimberley Reardon, 30, in May 2018, before her skin spiraled out of control (Collect/PA Real Life)

Despite suffering with mild baby eczema, her skin complaints only really started in her teens.

She said: My parents would usually use a cream on me as a baby which would work, but then the eczema appeared again when I was going through exams at 15.

It started on my back and spread to the creases in my elbows, with patches of redness.

It bothered me, but it hadnt spread to my face at that point, so I could just hide it.

Kimberleys eczema covering her face and neck in March 2020 (Collect/PA Real Life)

To ease the eczema, Kimberley was prescribed a steroid cream which was steadily increased in dosage to match her increasing flare ups. But hitting 20, the steroid creams seemed to stop working and during the next three years her condition intensified and spread to her face.

Kimberley Reardon, 30, and Scott Hannah, 31, have been together for 12 years (Collect/PA Real Life)

She said: I was studying for my social sciences degree at university, working part-time in a call centre and caring for my grandad because he was poorly and he had pneumonia.

Stress was definitely a trigger for my eczema, which went from some scaly patches to covering my whole body in red, inflamed dry skin that was just falling off my face.

Kimberleys arm was red raw in December 2020 (Collect/PA Real Life)

She added: My arms looked like red sleeves, while my legs were also covered and my neck was incredibly sore.

It was unmanageable. I was trying to use creams, emollients and moisturisers and wrapping myself in bandages, to try and help them to be absorbed into my skin.

Diagnosed with severe and widespread erythema at 23 a rash caused by injured or inflamed blood capillaries, usually in response to a drug, disease or infection Kimberleys skin became worse and worse.

Kimberley Reardon, 30, with makeup on for the first time in years (Collect/PA Real Life)

I wasnt functioning at all, I was exhausted, she said.

I felt ruined, like my body was fighting against me constantly.

It felt like I had severe sunburn over my whole body as if it was burning me from the inside out.

Kimberleys hand raw and peeling earlier this year, in April 2022 (Collect/PA Real Life)

After years fighting the eczema without success, Kimberley felt depressed, although she still tried to go out and have a normal life.

She said: I remember putting foundation on the top of my hands to try and cover the red patches,

One time a woman saw my hand when I pushed the lift button at work and she said, Oh! Have you been burnt? I felt so embarrassed.

I started wearing foundation to try and cover the patches, as well as long sleeves and big jumpers, even in the summer to try and hide my skin.

Kimberleys skin flaking and peeling in September 2020 (Collect/PA Real Life)

I felt so out of control of my skin that I started to micromanage everything else that I could to compensate.

Even though it hurt to move, I was hoovering six times a day to clear my skin up.

I was in so much pain, but I became obsessive about things.

I couldnt leave dishes out and I became totally over the top with cleaning and constantly checking my money, even though I knew I could pay my bills.

Kimberley Reardon, 30, with her boyfriend, Scott Hannah, 31(Collect/PA Real Life)

In 2018, Kimberleys skin condition became so bad she was hospitalised.

She said: My mum took one look at me and was horrified.

Ninety five per cent of my body was covered in red, swollen and burning skin.

I was losing too much fluid through my skin, where I was oozing out.

Kimberley Reardon on March 13, 2022 (Collect/PA Real Life)

She added: And the doctors said I was critically ill. My skin was so weak and I wasnt able to regulate my temperature.

After two weeks on an IV drip in hospital, Kimberley was placed on immunosuppressants and five months of oral steroids, to try and tame her excruciating eczema.

And when 2020 hit, she found herself completely bedbound.

Kimberley Reardon, 30, in March 2018, covering her red hands in foundation (Collect/PA Real Life)

She said: From January to March, my skin was the worst it had even been.

Doctors doubled my doses of immunosuppressants but nothing worked.

I had to have spare sheets to change and lie on every few hours. I was ruining the bed sheets where my skin was so flaky and oozy.

I was spending hours lying in really hot baths, because they seemed to be the only thing that relieved my skin, although it would be worse when I got out.

Kimberley said it was a blessing working from home in lockdown because of the pain and fear of judgement (Collect/PA Real Life)

She added: I was crying constantly and I didnt look like me at all.

I would think, Am I ever going to get better, is this it?'

When the March 2020 lockdown came in, it was a saving grace for Kimberley, as she was able to better manage her pain while she was working from home.

Prescribed new immunosuppressants, her skin briefly cleared but even then, she was plagued with a litany of other side effects.

Kimberley Reardon, 30, struggled immensely with her skin in 2020 (Collect/PA Real Life)

My skin was amazing but I was having other problems, she said.I was vomiting all the time, sleeping all the time and I couldnt keep food down.

Then, in July 2020, her skin flared up again so severely that she was hospitalised once more and signed off work for five months.

She said: I was bitten by an insect, which caused an abscess and cellulitis, a bacterial skin infection, because I had no immunity.

Kimberley trying to get through the pain in August 2020(Collect/PA Real Life)

Kimberley added: I was in hospital for two weeks on a drip again and antibiotics, followed by another three weeks of antibiotics at home.

I was bedbound, I barely got up and my poor boyfriend was carrying me to the toilet and running the bath for me.

I barely got changed, as it would take me hours to get dressed.

I lost my hair from the stress on my head, eyebrows and even my eyelashes.

And I didnt sleep for months because of the pain.

I was bedbound, I barely got up and my poor boyfriend was carrying me to the toilet and running the bath for me

Kimberley tried to go cold turkey without any medication to see if her body could heal itself, but nothing seemed to improve.

My face was covered, my body was covered, she said.

My boyfriend had to care for me, I couldnt do anything.

I spent my days in pain, just watching TV, or I sat in the bath for hours for some relief.

The worst thing for me was feeling like such a burden.

Kimberley Reardon, 30, with her clear skin in May 2022 (Collect/PA Real Life)

In a bid to help moisturising remedies to be absorbed and to stop her skin from weeping on everything, Kimberley would wrap herself up like a parcel.

She said: I was living in my eczema jammies, with long sleeves and long legs.

I would use bandages for my neck and my mum even got me a balaclava to sleep in at night, to stop my face sticking onto my pillows where it wept so much.

Kimberley felt very grateful for the support from her boyfriend, family and friends, but still felt mortified by her situation.

I was so embarrassed, I was completely mortified to be seen, she said.

If I went for a walk, I would just stare at the ground and never look anyone in the eye.

My boyfriend would always be so lovely. Whenever I started to feel bad, he would always bring me straight back up again.

In another attempt to clear her skin, in December 2020 Kimberley was prescribed a biologic an injection which targets the gene that causes inflammation which for three months cleared her skin.

Kimberley Reardon, 30, in September 2020 compared to now, with clear skin (Collect/PA Real Life)

I felt amazing, she said.

I was fatigued and achy from the side effects, but I felt so happy that something was working.

I had my first date night since 2019 at Frankie and Bennys with my boyfriend.

But, just as things were looking up, she developed a fungal infection across her arms and chest in February 2021.

It was so itchy. I was scratching so much I was ripping my skin off

She said: It was so itchy. I was scratching so much I was ripping my skin off.

So desperate to find something that worked, Kimberley even tried cryotherapy the use of extreme cold to freeze abnormal tissue for six weeks in July 2021.

She said: Once a week, I would stand in this freezing chamber, with temperatures at minus 110 to reduce inflammation.

It didnt work, it made me go purple, but I tried it as I was so desperate to do something and so scared of being bedbound again.

Just when she believed there was nothing else left to try, Kimberleys mum, Janey Reardon, 56, a retired receptionist, discovered the 9 cream in March this year.

Picking up a 30ml bottle for 8.99, she handed it to her daughter who cautiously applied some to a small patch on her finger.

She said: There had been no reaction in an hour, so I thought hopefully it would be okay.

I slathered it on and overnight and when I got up, my face was almost clear.

I couldnt believe it.

Using the cream every day, within one week, Kimberley was astounded to see that her skin was still miraculously clear.

And for the first time since 2019, she felt confident enough about her appearance to go to a coffee shop alone.

She said: I had a green tea in the coffee shop and for the first time in as long as I could remember, I wasnt worrying about people looking at my face.I had three date nights that week, one at the cinema and two foodie dates.

Even just going for a walk again was amazing.

Read the rest here:
Woman left balding and bedbound by chronic eczema clears the condition with a 9 face cream - The Independent

Tile Warehouse has surveyed the UK public to determine who abides by the five-second rule, and how its perceived differently across the country. This so-called rule says food is OK to eat if you pick it up in five seconds or less.

Results have revealed that the threat of contamination isnt stopping Brits from eating fallen food, with almost six in 10 (59%) agreeing that they would still eat food that had touched the floor. Of those who agreed, one in six (16%) preferred to only leave food for four to five seconds, following the favoured rule's steps.

Just over 1% claimed that they would eat food left on the floor for up to one minute. Even more shockingly, one in 20 people (5%) claimed that they would eat the food no matter how long it had been left on the floor.

The study found that women (56%) were less likely to eat food off the floor than men (61%). It seems that generational divides also extend to the five-second rule, with millennials (aged 24-42) the most likely to leave food on the floor the longest.

Members of this generation gave seven seconds as the average amount of time they would comfortably leave food on the floor before eating it. A closer look at the regions found that those in Scotland were likely to leave food on the floor for the longest amount of time with an average of 10 seconds.

In second place was Greater London, with residents admitting they would leave their food on the floor for a maximum of six seconds at a time. The research was conducted by Censuswide among 2,000 general consumers aged 18 and over in May 2022.

For more stories from where you live, visit InYourArea.

Read more:
Poll: Six in 10 people would eat food that has fallen on the floor - Coventry Live

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

Read more from the original source:
The itch that rashes: Treating and understanding eczema - El Paso Inc.

Jessica Simpson is famous for speaking her truth and that includes sharing details about her life with eczema.

I experienced it in junior high and high school, and after cheerleading, I would just put on my letter[man] jacket or a sweatshirt because people would hug me and be like, What is that on your arm? recalled the singer turned fashion mogul in an interview with People.

Im open about my insecurities and my flaws, and if I can help inspire anybody to feel better about themselves, thats why Im here, she added.

Simpsons willingness to discuss her challenges with atopic dermatitis (the most common form of eczema) has helped shine a light on a condition that many people would prefer to hide.

In fact, the emotional impact of the condition, along with the physical discomfort, may increase a persons risk of new depression and anxiety, according to a study published in 2020 in the Journal of Allergy and Clinical Immunology.

While eczema is common in children and young adults, it can appear at any age. The condition seems to affect the same number of female and male children, but studies have shown it is more common in adult women than men.

Simpson isnt the only superstar who has been candid about her private struggles with this skin condition that 1 in 10 Americans develop at some point during their lifetime. Here are some household names with atopic dermatitis.

Read the original post:
Celebrities With Eczema Speak Out - Everyday Health

THURSDAY, June 2, 2022 (HealthDay News) -- There are no differences in effectiveness between the four main types of moisturizers for childhood eczema, according to a study published online May 23 in The Lancet Child & Adolescent Health.

Matthew J. Ridd, Ph.D., from the University of Bristol in the United Kingdom, and colleagues compared the clinical effectiveness and safety of the four main emollient types. Children (aged 6 months to 12 years) with eczema were randomly assigned to lotions (137 children), creams (140 children), gels (135 children), and ointments (138 children).

The researchers observed no difference in eczema severity between emollient types over 16 weeks. Results remained unchanged even with multiple imputation, sensitivity, and subgroup analyses. There were also no differences seen in total number of adverse events between the treatment groups (36, 39, 40, and 35 percent for lotions, creams, gels, and ointments, respectively). However, stinging was less common with ointments (9 percent) compared with lotions (20 percent), creams (17 percent), and gels (19 percent).

"A study of this type has been long overdue. It has not been in the interest of the manufacturers to directly compare types of moisturizer in the way we have done in this trial," Ridd said in a statement. "Our findings challenge conventions about how often moisturizers need to be applied, which types are less likely to cause problems and which patients should be recommended certain types."

Abstract/Full Text

See the original post here:
Lotion, Cream, Gel, and Ointment Similarly Effective for Childhood Eczema - HealthDay News

Study findings provide evidence that preventative antibiotics improve health outcomes for babies and mothers, investigator say.

New research results showed that antibiotics given to women before a caesarean birth have no effect on the risk of early childhood conditions, such as asthma or eczema, according to investigators at the Universities of Birmingham and Warwick.

The results further support recommendations made by the National Institute for Health and Care Excellence (NIHCE), which claims that preventative antibiotics should be offered to mothers before undergoing C-sections. Updated in 2011, the guidance was created to minimize the risk of infection and notes that the mother will get the most benefit from antibiotics given shortly before C-sections compared with after the babys cord is clamped.

Although caesarean birth is common, so no known health harms are noted, if antibiotics are given before clamping the babys cord, it can cross the placenta and affect microbes in the babys gut. The microbes include bacteria that are expected to benefit the development and health of the immune system.

The research team compared the risk of allergy-related conditions in the first 5 years after birth in children born by both before and after the change in NIHCE guidelines, using records from several children born between 2006 and 2018 in United Kingdom-wide health care databases.

The results suggest that the policy of preventative antibiotics before a C-section has no effect on the risk of these early childhood conditions developing.

Maternal infections, such as wound infection, can be a risk in the period immediately after birth. Preventative antibiotics are of most benefit to the mother if given before the caesarean section is carried out, lead study author Dana Sumilo, MD, said in a statement. There is no known harm from these antibiotics to the babies born by caesarean birth, and our findings also suggest no effect on the risk of health conditions, such as asthma and eczema in early childhood.

Further, Andrew Shennan, clinical director at NIHR Clinical Research Network South London, added that these new findings are promising and provide more evidence that preventative antibiotics improve health outcomes for mothers and babies.

This arms clinicians with key evidence enabling them to ensure antibiotics are used wisely and at the optimum point for the most effective treatments, he said in the statement.

Reference

Antibiotics given shortly before caesarean birth not linked to asthma and eczema in young children. EurekAlert! News release. May 18, 2022. Accessed May 23, 2022. https://www.eurekalert.org/news-releases/952933

Follow this link:
Antibiotics Given Before C-sections Are Not Linked to Asthma, Eczema in Young Children - Pharmacy Times

New Jersey, United States TheEczema Skin-Care Products Marketreport is the result of extensive and expert research into theEczema Skin-Care Productsindustry. TheEczema Skin-Care ProductsMarketreport explains what the market is all about, the market prognosis, several segmentations, and everything that falls under the markets umbrella. It also looks at major and secondary market drivers, market share, potential sales volume, regional analysis, and the markets key segments. The research also includes key variables that contribute to the markets growth as well as elements that might stifle the markets growth. The professionals at VM Reports applied precise research techniques and other analyses.

PESTLE analysis and SWOT analysis are two of the analyses utilized in theEczema Skin-Care ProductsMarketresearch, and they shed light on numerous internal and external variables that affect the market in every situation. It also includes a section that identifies strengths, weaknesses, opportunities, and threats, as well as Porters five forces model.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=119446

There is also a section dedicated to significant actors and their plans, such as acquisitions, collaborations, and so on. The material in the Eczema Skin-Care Products Market research was gathered mostly via expert opinions, interviews, and surveys. Verified Market Research experts have created a Eczema Skin-Care Products Market research that is full of clarity, accuracy, and useful information. The data in the report is quite accurate and reliable, with no duplicates or mistakes.

Key Players Mentioned in the Eczema Skin-Care Products Market Research Report:

Alliance Pharma Plc., Bausch Health Companies Inc., Bayer AG., AbbVie Inc., Eli Lilly and Co., Johnson & Johnson, Mylan NV, Pfizer Inc., Encore Dermatology Inc., LEO Pharma AS., Loreal group, Nestle.

Eczema Skin-Care ProductsMarket Segmentation:

Eczema Skin-Care Products Market, By Type

Atopic Dermatitis Contact eczema Seborrheic eczema Nummular eczema Neurodermatitis Stasis dermatitis Dyshidrotic eczema

Eczema Skin-Care Products Market, By Product Type

Lotions and Ointments Cleansers Detergents Humidifiers

Eczema Skin-Care Products Market, By Distribution Channel

Online Off-line

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=119446

Eczema Skin-Care Products Market Report Scope

Key questions answered in the report:

1. Which are the five top players of the Eczema Skin-Care Products market?

2. How will the Eczema Skin-Care Products market change in the next five years?

3. Which product and application will take a lions share of the Eczema Skin-Care Products market?

4. What are the drivers and restraints of the Eczema Skin-Care Products market?

5. Which regional market will show the highest growth?

6. What will be the CAGR and size of the Eczema Skin-Care Products market throughout the forecast period?

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/eczema-skin-care-products-market/

Visualize Eczema Skin-Care Products Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Eczema Skin-Care Products Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Excerpt from:
Eczema Skin-Care Products Market Size, Scope and Forecast | Alliance Pharma Plc., Bausch Health Companies Inc., Bayer AG., AbbVie Inc., Eli Lilly and...